이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GoHealth 과거 수익 실적

과거 기준 확인 0/6

GoHealth의 수입은 연평균 -41.2%의 비율로 감소해 온 반면, Insurance 산업은 수입이 연평균 8.4%의 비율로 증가했습니다. 매출은 연평균 20.6%의 비율로 감소해 왔습니다.

주요 정보

-41.2%

수익 성장률

-34.3%

EPS 성장률

Insurance 산업 성장	8.0%
매출 성장률	-20.6%
자기자본 수익률	-34.4%
순이익	-9.1%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

GoHealth: Turning The Corner On Operating Cash Flow

May 28

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 10

수익 및 비용 분석

GoHealth 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:GOCO 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	737	-67	515	44
31 Dec 23	735	-67	507	43
30 Sep 23	527	-127	478	43
30 Jun 23	528	-132	477	43
31 Mar 23	544	-146	504	43
31 Dec 22	632	-150	585	46
30 Sep 22	1,012	-242	786	50
30 Jun 22	1,091	-233	859	50
31 Mar 22	1,129	-201	853	52
31 Dec 21	1,062	-189	782	48
30 Sep 21	1,059	2	611	43
30 Jun 21	1,010	-33	713	71
31 Mar 21	941	-20	630	64
31 Dec 20	877	-19	570	59
30 Sep 20	720	-27	462	55
30 Jun 20	664	16	310	48
31 Mar 20	611	10	277	47
31 Dec 19	540	16	249	46
31 Dec 18	226	28	102	16

양질의 수익: GOCO 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GOCO 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GOCO 은(는) 수익성이 없으며 지난 5년 동안 연간 41.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GOCO 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GOCO 은(는) 수익성이 없어 지난 해 수익 성장을 Insurance 업계( 37.3% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GOCO 현재 수익성이 없기 때문에 마이너스 자본 수익률( -34.43% )을 갖습니다.

GoHealth 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New minor risk - Shareholder dilution

New minor risk - Share price stability

New minor risk - Market cap size

GoHealth, Inc. Announces Chief Financial Officer Changes

GoHealth, Inc. Announces Resignation of Jason Schulz as Treasurer

GoHealth: Turning The Corner On Operating Cash Flow

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.12 loss in 1Q 2023)

GoHealth, Inc., Annual General Meeting, Jun 12, 2024

GoHealth, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 18%

Robbins Geller Rudman & Dowd LLP Announces a Notice of Pendency and Proposed Settlement of Class Action in the GoHealth, Inc. Securities Litigation

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$3.40 loss per share (vs US$17.72 loss in FY 2022)

GoHealth, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Price target increased by 43% to US$20.00

GoHealth, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Group of buyers cancelled the acquisition of remaining stake in GoHealth, Inc. (NasdaqCM:GOCO).

GoHealth, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GoHealth, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus EPS estimates fall by 17%

GoHealth, Inc. Announces Departure of Shane Cruz, the Current Chief Strategy Officer, Whose Employment Will Terminate as of June 30, 2023

Price target increased by 31% to US$14.02

Group of buyers submitted a non-binding proposal to acquire remaining stake in GoHealth, Inc. (NasdaqCM:GOCO) for approximately $330 million.

CEO & Director recently bought US$100k worth of stock

Consensus EPS estimates upgraded to US$3.74 loss

GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

GoHealth, Inc. Reiterates Earnings Guidance for the Year 2023

Consensus revenue estimates decrease by 15%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 34%

Consensus EPS estimates fall by 37%

Gohealth, Inc. Appoints Karolina Hilu as A Class III Director

Consensus forecasts updated

GoHealth, Inc. Receives Extension Notice from Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

GoHealth, Inc. to Report Q3, 2022 Results on Nov 10, 2022

GoHealth stock jumps 11% premarket on $50M private investment

GoHealth, Inc. announced delayed 10-Q filing

Price target decreased to US$1.10

GoHealth, Inc. to Report Q2, 2022 Results on Aug 15, 2022

GoHealth, Inc. Appoints Shane Cruz as Chief Strategy Officer

GoHealth, Inc. Names Jason Schulz as Chief Financial Officer

High number of new and inexperienced directors

GoHealth, Inc. Announces Executive Changes

GoHealth, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

GoHealth, Inc., Annual General Meeting, May 25, 2022

GoHealth, Inc. Announces the Resignation of Anita Pramoda from the Board of Directors

GoHealth, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 68%

GoHealth, Inc. Provides Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2021

Price target decreased to US$4.25

GoHealth: Painful Competition, Cost Controls Are Key

Price target decreased to US$5.79

GoHealth Looks To Q4 For Submission Growth

Co-Founder recently bought US$1.9m worth of stock

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.65 loss in 3Q 2020)

Price target decreased to US$8.50

Independent Director Rahm Emanuel has left the company

GoHealth: Post Sell-Off, A Fresh Look

Co-Founder recently bought US$1.2m worth of stock

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.002 profit in 2Q 2020)

GoHealth, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2021

Price target decreased to US$15.89

Chief Operating Officer exercised options and sold US$703k worth of stock

GoHealth amends credit agreement, lowers the interest rate to 4%